A joint project of the Graduate School, Peabody College, and the Jean & Alexander Heard Library

Title page for ETD etd-06162014-101705


Type of Document Master's Thesis
Author McCormack, Devin Rei
Author's Email Address devin.r.mccormack@vanderbilt.edu
URN etd-06162014-101705
Title In vivo Hyperspectral Imaging of Microvessel Response to Trastuzumab Treatment in Breast Cancer Xenografts
Degree Master of Science
Department Biomedical Engineering
Advisory Committee
Advisor Name Title
Melissa C. Skala Committee Chair
Craig L. Duvall Committee Member
Keywords
  • Optical Imaging
  • Image Processing
  • Vascular Imaging
  • Automated Image Quantification
Date of Defense 2014-06-16
Availability unrestricted
Abstract
HER2-amplified (HER2+) breast cancers are treated with the anti-HER2 monoclonal antibody trastuzumab. Although trastuzumab reduces production of the angiogenic factor VEGF in HER2+ tumors, the acute and sustained effects of trastuzumab on the tumor vasculature are not understood fully in trastuzumab-resistant tumors. Hyperspectral imaging is used to quantify microvessel density and hemoglobin oxygenation (sO2) of trastuzumab responsive and resistant breast cancers after antibody treatment in vivo. Microvessel dynamics are monitored over a 14 day time-course. Immunohistochemistry validates complementary markers of tumor cell and vascular response to treatment. Trastuzumab treatment in both responsive and resistant tumors resulted in decreased sO2 5 days after initial treatment when compared to IgG-treated controls (p<0.05). Responsive tumors showed significantly higher vessel density and significantly lower sO2 than all other groups at 5 days post-treatment (p<0.05). Distribution analysis of vessel sO2 showed a significant (p<0.05) shift of highly oxygenated vessels towards lower oxygenation over the time-course in both trastuzumab-treated responsive and resistant tumors. This study suggests that longitudinal hyperspectral imaging of microvessel sO2 and density could distinguish trastuzumab-responsive from trastuzumab-resistant tumors.
Files
  Filename       Size       Approximate Download Time (Hours:Minutes:Seconds) 
 
 28.8 Modem   56K Modem   ISDN (64 Kb)   ISDN (128 Kb)   Higher-speed Access 
  DRM_MS_Thesis_correct_TOC.pdf 1.51 Mb 00:06:58 00:03:35 00:03:08 00:01:34 00:00:08

Browse All Available ETDs by ( Author | Department )

If you have more questions or technical problems, please Contact LITS.